- Author’s View
- Published:
- Abi G. Yates1,2,
- Annie Khamhoung1,2 &
- Cameron S. McAlpine ORCID: orcid.org/0000-0002-9832-63451,2
volume24,pages 289–291 (2023)Cite this article
-
282 Accesses
-
6 Altmetric
-
Metrics details
Subjects
- Chronic inflammation
- Neuroimmunology
The nervous and immune systems are deeply intertwined. Although we know that coordination among these systems is essential for a healthy brain and goes awry in disease [1, 2], the nature of this biological crosstalk has remained unclear. Our recent discoveries [3, 4] shed light on new players that orchestrate this nervous-immune dialogue during neuroinflammation and neurodegeneration. Using multiple murine models and human tissue, we have identified interleukin-3 (IL-3) as a molecular messenger between the central nervous and peripheral immune systems that shapes brain inflammation and is an emerging therapeutic target.
IL-3 was one of the first interleukins discovered [5]. Despite its early provenance, its diverse functions have remained ill-defined. IL-3 is a member of the colony stimulating factor (CSF) family and its actions were initially described in the bone marrow where it regulates hematopoiesis and stimulates the myeloproliferation of hematopoietic stem cells during inflammatory need [6, 7]. However, IL-3 is dispensable for steady state hematopoiesis and its roles beyond the bone marrow have remained unclear. While researchers have uncovered important functions of allied growth factors like macrophage colony stimulating factor (M-CSF) and granulocyte macrophage (GM)-CSF in the brain, whether IL-3 acts in the central nervous system (CNS) and contributes to pathology was largely unknown.
This is a preview of subscription content, access via your institution
Access options
Change institution
Buy or subscribe
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Learn more
Prices may be subject to local taxes which are calculated during checkout
References
Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L. The immunology of multiple sclerosis. Nat Rev Immunol. 2022;22:734–50.
Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17:157–72.
McAlpine CS, Park J, Griciuc A, Kim E, Choi SH, Iwamoto Y, et al. Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease. Nature. 2021;595:701–6.
Kiss MG, Mindur JE, Yates AG, Lee D, Fullard JF, Anzai A, et al. Interleukin-3 coordinates glial–peripheral immune crosstalk to incite multiple sclerosis. Immunity. 2023;56:1502–14.
Pluznik DH, Sachs L. The cloning of normal ‘mast’ cells in tissue culture. J Cell Physiol. 1965;66:319–24.
Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science. 2015;347:1260–5.
Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity. 2019;50:796–811.
Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359–62.
Frei K, Bodmer S, Schwerdel C, Fontana A. Astrocyte-derived interleukin 3 as a growth factor for microglia cells and peritoneal macrophages. J Immunol. 1986;137:3521–7.
Lim JC, Lu W, Beckel JM, Mitchell CH. Neuronal release of cytokine IL-3 triggered by mechanosensitive autostimulation of the P2X7 receptor is neuroprotective. Front Cell Neurosci. 2016;10. https://doi.org/10.3389/FNCEL.2016.00270.
Wang ZB, Ma YH, Sun Y, Tan L, Wang HF, Yu JT. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer’s disease. J Neuroinflammation. 2022;19:1–11.
Charabati M, Wheeler MA, Weiner HL, Quintana FJ. Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting. Cell. 2023;186:1309–27.
Luo X, Li M, Huang L, Nho K, Deng M, Chen Q, et al. The interleukin 3 gene (IL3) contributes to human brain volume variation by regulating proliferation and survival of neural progenitors. PLoS ONE. 2012;7:e50375.
Acknowledgements
This work was funded by the National Institutes of health (NIH) R01AG082185, R01HL158534, R00HL151750, the Cure Alzheimer’s Fund, and an ISMMS Karen Strauss Cook Research Scholar Award (to CSM).
Author information
Authors and Affiliations
Cardiovascular Research Institute and the Department of Medicine, Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Abi G. Yates,Annie Khamhoung&Cameron S. McAlpine
Friedman Brain Institute and the Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Abi G. Yates,Annie Khamhoung&Cameron S. McAlpine
Authors
- Abi G. Yates
View author publications
You can also search for this author in PubMedGoogle Scholar
- Annie Khamhoung
View author publications
You can also search for this author in PubMedGoogle Scholar
- Cameron S. McAlpine
View author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
AGY and AK wrote and edited the manuscript. CSM supervised, conceived of the manuscript, designed the figure, and wrote the manuscript.
Corresponding author
Correspondence to Cameron S. McAlpine.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yates, A.G., Khamhoung, A. & McAlpine, C.S. Interleukin-3 gets a fresh start in the brain. Genes Immun 24, 289–291 (2023). https://doi.org/10.1038/s41435-023-00231-w
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41435-023-00231-w
